

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Angus McDougall Caithness
Date of last notice	16 April 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Banquo Consulting Pty Ltd - Mr Caithness is a director Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund - Mr Caithness is a director of the trustee and beneficiary
Date of change	2 September 2024
No. of securities held prior to change	<u>Direct</u> 5,751,441 Ordinary shares 1,000,000 Retention Share Rights <u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 5,413,333 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights <i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 316,667 Ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027
Number acquired	2,000,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil – issue of Unlisted Options under the Company's Long Term Incentive Plan as approved by shareholders at the Company's AGM on 29 August 2024
No. of securities held after change	<p><u>Direct</u> 5,751,441 Ordinary shares 1,000,000 Retention Share Rights 2,000,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027</p> <p><u>Indirect</u> <i>Banquo Consulting Pty Ltd</i> 5,413,333 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights</p> <p><i>Angus Caithness SMSF Pty Ltd as trustee for the Caithness Superannuation Fund</i> 316,667 Ordinary shares</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Unlisted Options under the Company's Long Term Incentive Plan as approved by shareholders at the Company's AGM on 29 August 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.
 Introduced 30/9/2001.

Name of entity	Little Green Pharma Ltd
ACN	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Fleta Jennifer Solomon
Date of last notice	16 April 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Fleta Solomon Super Pty Ltd as trustee for Solomon Super Fund - Ms Solomon is a director of the trustee and beneficiary
Date of change	2 September 2024
No. of securities held prior to change <small>* opening balance from previous interest notice reduced by 36,000 for conversion of share rights on 24 April 2023</small>	<u>Direct</u> 20,723,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights <u>Indirect</u> 1,150,000 fully paid ordinary shares
Class	Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027
Number acquired	1,200,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – issue of Unlisted Options under the Company's Long Term Incentive Plan as approved by shareholders at the Company's AGM on 29 August 2024
No. of securities held after change	<p><u>Direct</u> 20,723,216 fully paid ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights 500,000 Class I Performance Rights 500,000 Class J Performance Rights 500,000 Class K Performance Rights 1,000,000 Retention Rights 1,200,000 Unlisted Options, exercisable at \$0.138 each, expiring 31 July 2027</p> <p><u>Indirect</u> 1,150,000 fully paid ordinary shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options under the Company's Long Term Incentive Plan as approved by shareholders at the Company's AGM on 29 August 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.